Acceptability and Tolerance Study of a New Oral Nutritional Supplement (ONS)

Aymes International Limited16 enrolled

Overview

Tolerance and Acceptability of new oral nutritional supplement - AYMES PARIS

To evaluate tolerance and acceptability of AYMES PARIS in patients requiring supplementary oral nutritional support compared with currently available alternatives, measuring outcomes of GI effects, Compliance, product preference,convenience etc. To obtain data to support an ACBS submissions for AYMES PARIS (to allow for prescription in the community at NHS expense).

Study Type

INTERVENTIONAL

Allocation

Masking

NONE

Enrollment

Conditions

Malnutrition

Interventions

AYMES PARISDIETARY_SUPPLEMENT

AYMES PARIS is a powdered, high energy, oral nutritional supplement to be mixed with milk as a drink. It provides 320 kcal and 12.2 g protein per 139 ml serving. It is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients (≥18 years) who are able to communicate their views regarding acceptability. * Patients established on an oral nutritional supplement, being prescribed 1-2 ONS providing approximately 300kcal/day * Patients expected to require oral nutritional supplementation for at least 2 further weeks. * Informed consent obtained. Exclusion Criteria: * Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study * Patients requiring a milk-free diet * Patients with medical or dietary contraindication to any feed ingredients (see appendix 2 of protocol for full list) * Patients with significant renal or hepatic impairment * Patients with swallowing impairment requiring thickened fluids * Patients with inflammatory bowel disease or previous bowel resection.

Outcomes

Primary Outcomes

GI side effects when using AYMES PARIS

Recording of absence/presence of any nausea, vomiting, abdominal pain, bloating / flatulence, when using AYMES PARIS as assessed by presence / absence of side effect compared to baseline period

Time frame: 9 DAYS

Secondary Outcomes

Change to bodyweight of subjects when using AYMES PARIS

Recording of bodyweight (in kg) at start of study, start of intervention and end of intervention for comparison to investigate any trend in weight change during the intervention period compared to baseline

Time frame: 9 DAYS

Compliance with prescription of AYMES PARIS

Recording of amount of AYMES PARIS consumed by subjects compared to amount prescribed. Good compliance = \>80% of prescribed being consumed. Same data collected for baseline product and compared with that of AYMES PARIS

Time frame: 9 DAYS

Bowel habits of subjects when using AYMES PARIS - frequency

Recording of bowel habits whilst subjects consuming AYMES PARIS, as assessed by frequency of bowel movements (number of stools per day) and compared to same data recorded during baseline period

Time frame: 9 days

Bowel habits of subjects when using AYMES PARIS - stool consistency

Recording of bowel habits whilst subjects consuming AYMES PARIS, as assessed by consistency of stools (assessed by Bristol Stool Chart) and compared to same data recorded during baseline period

Time frame: 9 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.